Latest Sales Performance News

BPH Global Ltd has recorded its second highest monthly seaweed sales since May 2025, driven by a strategic shift towards independent operations in Indonesia. The company’s aggregate sales now exceed A$2.15 million, underpinning its growth ambitions for 2026.

Botanix Pharmaceuticals reported a robust 28% increase in net revenue for Sofdra in Q2 FY26, driven by a 24% rise in prescriptions and a growing US sales team. The company maintains a strong cash position while navigating higher operating costs.

RooLife Group Ltd has reported a remarkable doubling of its coffee and food sales in China, surpassing A$2.1 million in December 2025 and signaling strong momentum in its data-driven e-commerce strategy.

ARB Corporation’s half-year results reveal a modest sales dip driven by Australian OEM challenges, while robust US export growth offers a silver lining.

Yancoal has reported record coal production and sales for 2025, achieving near the top of its guidance range with improved realised prices despite challenging market conditions. The company’s robust cash position and disciplined cost management position it well for future growth.

Jupiter Energy reported steady oil production and US$1.6 million in domestic sales for Q4 2025, while completing integration of its West Zhetybai oilfield into a regional gas utilisation network.

Neuren Pharmaceuticals has affirmed the material impact of Acadia’s projection that DAYBUE global net sales could reach approximately US$700 million by 2028, underpinning its royalty revenue outlook.

The Calmer Co. International Limited has reported its highest ever monthly sales of $910,767 in December 2025, driven by strong wholesale growth and expanding US market presence.

Biome Australia Limited has reported a record-breaking quarter and half-year sales performance, driven by strong demand for its clinically-backed probiotic products. Revenue surged over 40% compared to the previous year, defying typical seasonal slowdowns.

Zoono Group Limited has responded to ASX queries confirming ongoing collaboration with OSY Group Limited, acknowledging delays in meeting sales targets but highlighting steady contract progress and future order potential.

Aumake Limited has obtained a Hong Kong pharmaceutical wholesale licence, enabling it to launch up to five online over-the-counter medicine stores targeting Chinese consumers. This strategic move positions the company to tap into China’s rapidly expanding OTC market.

Cedar Woods Properties has raised its FY26 net profit guidance to at least 20% growth, driven by strong sales and faster project delivery, setting the stage for record earnings and higher dividends.